X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1881) 1881
Publication (83) 83
Book Review (23) 23
Book / eBook (4) 4
Book Chapter (4) 4
Web Resource (4) 4
Conference Proceeding (3) 3
Magazine Article (3) 3
Dissertation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1714) 1714
filgrastim (1595) 1595
female (1128) 1128
granulocyte colony-stimulating factor - therapeutic use (1024) 1024
middle aged (917) 917
male (880) 880
adult (845) 845
recombinant proteins (826) 826
oncology (758) 758
index medicus (684) 684
aged (674) 674
colony-stimulating factor (608) 608
chemotherapy (573) 573
antineoplastic combined chemotherapy protocols - therapeutic use (506) 506
granulocyte colony-stimulating factor - administration & dosage (475) 475
hematology (472) 472
treatment outcome (405) 405
granulocyte colony-stimulating factor (393) 393
neutropenia (387) 387
recombinant proteins - therapeutic use (365) 365
neutropenia - chemically induced (356) 356
polyethylene glycols (349) 349
g-csf (345) 345
cancer (337) 337
antineoplastic combined chemotherapy protocols - adverse effects (330) 330
neutropenia - drug therapy (300) 300
granulocyte colony-stimulating factor - adverse effects (255) 255
febrile neutropenia (250) 250
pegfilgrastim (247) 247
pharmacology & pharmacy (244) 244
transplantation (244) 244
adolescent (235) 235
breast neoplasms - drug therapy (231) 231
neutropenia - prevention & control (222) 222
antineoplastic agents - adverse effects (198) 198
drug administration schedule (197) 197
retrospective studies (193) 193
neoplasms - drug therapy (192) 192
granulocyte colony-stimulating factor - pharmacology (185) 185
single-administration pegfilgrastim (167) 167
immunology (166) 166
cyclophosphamide - administration & dosage (165) 165
therapy (165) 165
breast-cancer (161) 161
daily filgrastim (161) 161
dose-response relationship, drug (156) 156
hematopoietic stem cell mobilization - methods (154) 154
hematopoietic stem cell transplantation (153) 153
antineoplastic combined chemotherapy protocols - administration & dosage (147) 147
care and treatment (146) 146
medicine & public health (145) 145
antineoplastic agents - therapeutic use (143) 143
combined modality therapy (142) 142
breast cancer (140) 140
recombinant proteins - administration & dosage (137) 137
non-hodgkins-lymphoma (136) 136
animals (133) 133
leukocyte count (133) 133
filgrastim - therapeutic use (132) 132
double-blind (130) 130
time factors (129) 129
research (127) 127
cyclophosphamide (126) 126
multicenter (126) 126
aged, 80 and over (124) 124
transplantation, autologous (124) 124
doxorubicin - administration & dosage (123) 123
risk factors (123) 123
young adult (118) 118
prospective studies (114) 114
child (113) 113
granulocyte colony-stimulating factor - economics (105) 105
neoplasm staging (105) 105
stem cells (103) 103
drug therapy (102) 102
mobilization (102) 102
disease-free survival (99) 99
health aspects (98) 98
high-dose chemotherapy (95) 95
recombinant proteins - adverse effects (94) 94
drug therapy, combination (92) 92
hematopoietic stem cells (92) 92
analysis (89) 89
breast neoplasms - pathology (89) 89
bone-marrow transplantation (87) 87
doxorubicin (87) 87
etoposide - administration & dosage (86) 86
neutrophils (84) 84
cost-benefit analysis (83) 83
neutropenia - etiology (83) 83
remission induction (83) 83
hematopoietic stem cell mobilization (82) 82
leukemia (82) 82
paclitaxel - administration & dosage (82) 82
child, preschool (81) 81
lymphoma (81) 81
survival analysis (81) 81
hematology, oncology and palliative medicine (80) 80
health care sciences & services (79) 79
lymphoma, non-hodgkin - drug therapy (79) 79
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1804) 1804
French (20) 20
Spanish (20) 20
Japanese (17) 17
German (13) 13
Russian (8) 8
Italian (5) 5
Polish (4) 4
Chinese (3) 3
Czech (3) 3
Portuguese (2) 2
Swedish (2) 2
Hungarian (1) 1
Lithuanian (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Psycho‐Oncology, ISSN 1057-9249, 07/2013, Volume 22, Issue 7, pp. 1674 - 1675
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 2014, Issue 10, p. CD003039
Journal Article
Seminars in Oncology, ISSN 0093-7754, 10/2011, Volume 38, Issue 5, pp. 635 - 647
Hematopoietic growth factors (HGFs) continue to be the most widely prescribed class of medications for patients with myelodysplastic syndromes (MDS), despite... 
TUMOR-NECROSIS-FACTOR | LOW-RISK | COLONY-STIMULATING FACTOR | ONCOLOGY | GM-CSF | RECOMBINANT-HUMAN-ERYTHROPOIETIN | ERYTHROID RESPONSE | TRANS-RETINOIC ACID | QUALITY-OF-LIFE | INTERNATIONAL WORKING GROUP | DARBEPOETIN-ALPHA | Recombinant Proteins - therapeutic use | Benzoates - adverse effects | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Erythropoietin - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Erythropoietin - adverse effects | Thrombopoietin - therapeutic use | Recombinant Proteins - adverse effects | Thrombopoietin - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Filgrastim | Patient Selection | Receptors, Fc - therapeutic use | Erythropoietin - analogs & derivatives | Drug-Related Side Effects and Adverse Reactions | Colony-Stimulating Factors - adverse effects | Epoetin Alfa | Hydrazines - administration & dosage | Myelodysplastic Syndromes - drug therapy | Recombinant Fusion Proteins - administration & dosage | Colony-Stimulating Factors - therapeutic use | Pyrazoles - adverse effects | Granulocyte Colony-Stimulating Factor - adverse effects | Erythropoietin - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Hydrazines - therapeutic use | Hematinics - therapeutic use | Polyethylene Glycols | Hematinics - adverse effects | Granulocyte Colony-Stimulating Factor - therapeutic use | Hematinics - administration & dosage | Recombinant Proteins - administration & dosage | Benzoates - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects | Pyrazoles - administration & dosage | Thrombopoietin - adverse effects | Receptors, Fc - administration & dosage | Darbepoetin alfa | Colony-Stimulating Factors - administration & dosage | Granulocyte Colony-Stimulating Factor - administration & dosage | Hydrazines - adverse effects
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2018, Volume 74, Issue 3, pp. 315 - 321
The purpose of this study is to describe the effectiveness of biosimilar filgrastim and original granulocyte colony-stimulating factors (G-CSFs), lenograstim... 
Observational study | Biomedicine | Granulocyte colony-stimulating factor | Biosimilar pharmaceuticals | Breast cancer | Pharmacology/Toxicology | Filgrastim | Febrile neutropenia | MORTALITY | METAANALYSIS | SINGLE-ADMINISTRATION PEGFILGRASTIM | RECEIVING CHEMOTHERAPY | PRIMARY PROPHYLAXIS | RISK | HOSPITALIZATION | ADJUVANT DOCETAXEL | TAC | PHARMACOLOGY & PHARMACY | CLINICAL-PRACTICE | Recombinant Proteins - therapeutic use | Doxorubicin - therapeutic use | Febrile Neutropenia - chemically induced | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Febrile Neutropenia - prevention & control | Polyethylene Glycols - therapeutic use | Cyclophosphamide - therapeutic use | Incidence | Pharmacoepidemiology - methods | Taxoids - therapeutic use | Adult | Female | Filgrastim - therapeutic use | Retrospective Studies | Breast - pathology | Taxoids - adverse effects | Febrile Neutropenia - physiopathology | Severity of Illness Index | Febrile Neutropenia - epidemiology | Risk Factors | Hematologic Agents - therapeutic use | Hospitals, University | Granulocyte Colony-Stimulating Factor - therapeutic use | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast - drug effects | Breast Neoplasms - pathology | Spain - epidemiology | Neoplasm Staging | Doxorubicin - adverse effects | Cohort Studies | Prevention | Care and treatment | Cancer patients | Chemotherapy | Analysis | Hyperthermia | Fever | Neutropenia | Cancer | Health care | Drugs | Statistical analysis | Colonies | Prophylaxis | Data processing | Pharmacology | Drug development | Patients | Doxorubicin | Cyclophosphamide | Side effects | Granulocytes | Data collection | Breast | Colony-stimulating factor | Leukocytes (granulocytic)
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2016, Volume 11, Issue 2, p. e0148901
Objective This study aims to compare the cost-effectiveness of various strategies of myeloid growth factor prophylaxis for reducing the risk of febrile... 
UNITED-STATES | SECONDARY PROPHYLAXIS | FILGRASTIM | MULTIDISCIPLINARY SCIENCES | RISK | AGGRESSIVE LYMPHOMA | SOLID TUMOR | ELDERLY-PATIENTS | CANCER | Recombinant Proteins - therapeutic use | Doxorubicin - therapeutic use | Markov Chains | Chemoprevention - economics | Granulocyte Colony-Stimulating Factor - economics | Humans | Febrile Neutropenia - prevention & control | Cyclophosphamide - therapeutic use | Filgrastim | Prednisone - economics | Lymphoma, Non-Hodgkin - complications | Antineoplastic Combined Chemotherapy Protocols - economics | Lymphoma, Non-Hodgkin - drug therapy | Biosimilar Pharmaceuticals - therapeutic use | Cyclophosphamide - economics | Polyethylene Glycols | Febrile Neutropenia - epidemiology | Vincristine - economics | Antibodies, Monoclonal, Murine-Derived - economics | Doxorubicin - economics | Probability | Biosimilar Pharmaceuticals - economics | Granulocyte Colony-Stimulating Factor - therapeutic use | Recombinant Proteins - economics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Singapore - epidemiology | Cost-Benefit Analysis | Vincristine - therapeutic use | Febrile Neutropenia - economics | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - economics | Prevention | Complications and side effects | Usage | Chemotherapy | Non-Hodgkin's lymphomas | Drug therapy | Growth factors | Health aspects | Neutropenia | Cancer | Sensitivity analysis | Statistical analysis | Colonies | Prophylaxis | Risk reduction | Oncology | Markov chains | Cancer therapies | Patients | Lymphoma | Studies | Granulocytes | Granulocyte colony-stimulating factor | Pharmacy | Strategy | Colony-stimulating factor | Lymphomas | Cost analysis | Leukocytes (granulocytic)
Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 6, p. e0157245
Background Allogeneic human islet transplantation is an effective therapy for the treatment of patients with Type 1 Diabetes (T1D). The low number of islet... 
TUMOR-NECROSIS-FACTOR | PRIMARY NONFUNCTION | DENDRITIC CELLS | IMMUNOSUPPRESSION | MULTIDISCIPLINARY SCIENCES | INSULIN INDEPENDENCE | IN-VIVO | REGULATORY T-CELLS | INDUCTION | ATP | TRANSPLANTATION | Hypoglycemic Agents - therapeutic use | Islets of Langerhans - drug effects | Antibodies, Monoclonal, Humanized - therapeutic use | Islets of Langerhans - physiology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Hematologic Agents - therapeutic use | Immunoglobulin G - therapeutic use | Islets of Langerhans Transplantation - methods | Hyperglycemia - drug therapy | Neutropenia - drug therapy | Transplantation, Homologous | Neutropenia - etiology | Islets of Langerhans Transplantation - adverse effects | Venoms - therapeutic use | Adult | Aged | Filgrastim - therapeutic use | Hyperglycemia - etiology | Retrospective Studies | Graft Survival - drug effects | Peptides - therapeutic use | Complications and side effects | Care and treatment | Usage | Type 1 diabetes | Research | Health aspects | Diabetes therapy | Quality of life | Health sciences | Demography | Transplants & implants | Peptides | Syngeneic grafts | Medical services | Transplantation | Diabetes mellitus (insulin dependent) | Glucose | Grafting | Demographic variables | Infusion | Demographics | Hyperglycemia | Allografts | Immunology | Granulocyte colony-stimulating factor | Etanercept | Infliximab | Rodents | CD25 antigen | Tumor necrosis factor-TNF | Physiology | Public health | Neutropenia | Medical treatment | Diabetes mellitus | Organs | Pancreatic islet transplantation | Transplants | Data processing | Tumor necrosis factor-α | Hypoglycemia | Patients | Survival | Insulin | Immunosuppression | Grafts | Islet cells | Monoclonal antibodies | Pancreas transplantation | Diabetes
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2008, Volume 14, Issue 6, pp. 641 - 650
Abstract We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide (Cy) to prevent graft rejection and graft-versus-host disease... 
Hematology, Oncology and Palliative Medicine | Bone marrow transplantation | Cyclophosphamide | Histocompatibility antigens | Conditioning regimens | Lymphoma | Leukemia | TOTAL-BODY IRRADIATION | leukemia | ADULT PATIENTS | IMMUNE RECONSTITUTION | lymphoma | UNRELATED DONORS | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | bone marrow transplantation | TRANSPLANTATION | histocompatibility antigens | CORD BLOOD TRANSPLANTATION | DRUG-INDUCED TOLERANCE | cyclophosphamide | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MYCOPHENOLATE-MOFETIL | conditioning regimens | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Recombinant Proteins | Bone Marrow Transplantation - methods | Cyclophosphamide - therapeutic use | Filgrastim | Transplantation, Homologous | Bone Marrow Transplantation - immunology | Adult | Female | Transplantation Conditioning - methods | Mycophenolic Acid - administration & dosage | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Drug Administration Schedule | Graft Survival | Postoperative Complications - epidemiology | Vidarabine - analogs & derivatives | Granulocyte Colony-Stimulating Factor - therapeutic use | Postoperative Care - methods | Blood Component Transfusion | Hematologic Neoplasms - surgery | Disease-Free Survival | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Hemoglobinuria, Paroxysmal - surgery | Cyclophosphamide - pharmacology | Graft vs Host Disease - prevention & control | Aged | Vidarabine - administration & dosage | Histocompatibility | Antimitotic agents | Evaluation | Mortality | Bone marrow | Dosage and administration | Transplantation | Antineoplastic agents | T cells | Cancer | Index Medicus
Journal Article
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 02/2018, Volume 78, Issue 2, pp. 303 - 309.e4
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2017, Volume 39, Issue 6, pp. 1161 - 1170
Abstract Purpose With the emergence of biosimilar filgrastim to the market, there is a gradual decrease in the listed price of the originator product of... 
Internal Medicine | Medical Education | filgrastim | treatment | febrile neutropenia | cost-effectiveness analysis | MULTICENTER | COLONY-STIMULATING FACTOR | SINGAPORE | CHEMOTHERAPY | SOCIETY | 2010 UPDATE | CANCER-PATIENTS | CLINICAL-PRACTICE GUIDELINE | PHARMACOLOGY & PHARMACY | FEVER | LIFE | Anti-Bacterial Agents - economics | Models, Theoretical | Quality-Adjusted Life Years | Neoplasms - economics | Humans | Lymphoma - economics | Neoplasms - drug therapy | Anti-Bacterial Agents - therapeutic use | Filgrastim - economics | Lymphoma - drug therapy | Febrile Neutropenia - drug therapy | Cost-Benefit Analysis | Adult | Filgrastim - therapeutic use | Decision Trees | Febrile Neutropenia - economics | Usage | Granulocyte colony-stimulating factor | Analysis | Pharmacy | Drugstores | Lymphomas | Cost benefit analysis | Health aspects | Neutropenia | Medical research | Medicine, Experimental | Risk | Cancer therapies | Marketing | Granulocytes | Emergence | Robustness | Cost engineering | Sensitivity analysis | Risk groups | Decision making | Probability theory | Neutrophils | Health risks | Consumer Price Index | Markets | Antimicrobial agents | Time measurement | Probabilistic methods | Injection | Decision analysis | Patients | Fever | Cost control | Chemotherapy | Sensitivity | Hospitals | Infectious diseases | Antibiotics | Sepsis | Solid tumors | Clinical medicine | Cost analysis | Tumors | Cancer
Journal Article